Closing the system: production of viral antigen-presenting dendritic cells eliciting specific $ CD8^{+} $ T cell activation in fluorinated ethylene propylene cell culture bags
Background A major obstacle to anti-viral and -tumor cell vaccination and T cell immunotherapy is the ability to produce dendritic cells (DCs) in a suitable clinical setting. It is imperative to develop closed cell culture systems to accelerate the translation of promising DC-based cell therapy products to the clinic. The objective of this study was to investigate whether viral antigen-loaded monocyte-derived DCs (Mo-DCs) capable of eliciting specific T cell activation can be manufactured in fluorinated ethylene propylene (FEP) bags. Methods Mo-DCs were generated through a protocol applying cytokine cocktails combined with lipopolysaccharide or with a CMV viral peptide antigen in conventional tissue culture polystyrene (TCPS) or FEP culture vessels. Research-scale (< 10 mL) FEP bags were implemented to increase R&D throughput. DC surface marker profiles, cytokine production, and ability to activate antigen-specific cytotoxic T cells were characterized. Results Monocyte differentiation into Mo-DCs led to the loss of CD14 expression with concomitant upregulation of CD80, CD83 and CD86. Significantly increased levels of IL-10 and IL-12 were observed after maturation on day 9. Antigen-pulsed Mo-DCs activated antigen-responsive $ CD8^{+} $ cytotoxic T cells. No significant differences in surface marker expression or tetramer-specific T cell activating potency of Mo-DCs were observed between TCPS and FEP culture vessels. Conclusions Our findings demonstrate that viral antigen-loaded Mo-DCs produced in downscaled FEP bags can elicit specific T cell responses. In view of the dire clinical need for closed system DC manufacturing, FEP bags represent an attractive option to accelerate the translation of promising emerging DC-based immunotherapies..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Journal of translational medicine - 18(2020), 1 vom: 09. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bastien, Jean-Philippe [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Cellular therapy |
|---|
| doi: |
10.1186/s12967-020-02543-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR041262581 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR041262581 | ||
| 003 | DE-627 | ||
| 005 | 20230519155055.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201102s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12967-020-02543-1 |2 doi | |
| 035 | |a (DE-627)SPR041262581 | ||
| 035 | |a (SPR)s12967-020-02543-1-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Bastien, Jean-Philippe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Closing the system: production of viral antigen-presenting dendritic cells eliciting specific $ CD8^{+} $ T cell activation in fluorinated ethylene propylene cell culture bags |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background A major obstacle to anti-viral and -tumor cell vaccination and T cell immunotherapy is the ability to produce dendritic cells (DCs) in a suitable clinical setting. It is imperative to develop closed cell culture systems to accelerate the translation of promising DC-based cell therapy products to the clinic. The objective of this study was to investigate whether viral antigen-loaded monocyte-derived DCs (Mo-DCs) capable of eliciting specific T cell activation can be manufactured in fluorinated ethylene propylene (FEP) bags. Methods Mo-DCs were generated through a protocol applying cytokine cocktails combined with lipopolysaccharide or with a CMV viral peptide antigen in conventional tissue culture polystyrene (TCPS) or FEP culture vessels. Research-scale (< 10 mL) FEP bags were implemented to increase R&D throughput. DC surface marker profiles, cytokine production, and ability to activate antigen-specific cytotoxic T cells were characterized. Results Monocyte differentiation into Mo-DCs led to the loss of CD14 expression with concomitant upregulation of CD80, CD83 and CD86. Significantly increased levels of IL-10 and IL-12 were observed after maturation on day 9. Antigen-pulsed Mo-DCs activated antigen-responsive $ CD8^{+} $ cytotoxic T cells. No significant differences in surface marker expression or tetramer-specific T cell activating potency of Mo-DCs were observed between TCPS and FEP culture vessels. Conclusions Our findings demonstrate that viral antigen-loaded Mo-DCs produced in downscaled FEP bags can elicit specific T cell responses. In view of the dire clinical need for closed system DC manufacturing, FEP bags represent an attractive option to accelerate the translation of promising emerging DC-based immunotherapies. | ||
| 650 | 4 | |a Cellular therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Dendritic cell |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Fluorinated polymers |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Immunotherapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Monocyte |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Polystyrene |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Scale-down |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Fekete, Natalie |e verfasserin |4 aut | |
| 700 | 1 | |a Beland, Ariane V. |e verfasserin |4 aut | |
| 700 | 1 | |a Lachambre, Marie-Paule |e verfasserin |4 aut | |
| 700 | 1 | |a Laforte, Veronique |e verfasserin |4 aut | |
| 700 | 1 | |a Juncker, David |e verfasserin |4 aut | |
| 700 | 1 | |a Dave, Vibhuti |e verfasserin |4 aut | |
| 700 | 1 | |a Roy, Denis-Claude |e verfasserin |4 aut | |
| 700 | 1 | |a Hoesli, Corinne A. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of translational medicine |d London : BioMed Central, 2003 |g 18(2020), 1 vom: 09. Okt. |w (DE-627)SPR028930886 |w (DE-600)2118570-0 |x 1479-5876 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2020 |g number:1 |g day:09 |g month:10 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12967-020-02543-1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2020 |e 1 |b 09 |c 10 | ||